Home / Healthcare / Neuroblastoma - Pipeline Review, H1 2016

Neuroblastoma - Pipeline Review, H1 2016

Published: May 2016 | No Of Pages: 383 | Published By: Global Markets Direct

Neuroblastoma - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Neuroblastoma - Pipeline Review, H1 2016’, provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects
- The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
Introduction 6
Neuroblastoma Overview 7
Therapeutics Development 8
Neuroblastoma - Therapeutics under Development by Companies 10
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 14
Neuroblastoma - Pipeline Products Glance 16
Neuroblastoma - Products under Development by Companies 19
Neuroblastoma - Products under Investigation by Universities/Institutes 24
Neuroblastoma - Companies Involved in Therapeutics Development 25
Neuroblastoma - Therapeutics Assessment 71
Drug Profiles 87
Neuroblastoma - Recent Pipeline Updates 263
Neuroblastoma - Dormant Projects 360
Neuroblastoma - Discontinued Products 363
Neuroblastoma - Product Development Milestones 364
Appendix 371

Number of Products under Development for Neuroblastoma, H1 2016 19
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Development by Companies, H1 2016 (Contd..1) 22
Number of Products under Development by Companies, H1 2016 (Contd..2) 23
Number of Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Development, H1 2016 29
Products under Development by Companies, H1 2016 30
Products under Development by Companies, H1 2016 (Contd..1) 31
Products under Development by Companies, H1 2016 (Contd..2) 32
Products under Development by Companies, H1 2016 (Contd..3) 33
Products under Development by Companies, H1 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H1 2016 35
Neuroblastoma - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 36
Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 37
Neuroblastoma - Pipeline by Advanced Accelerator Applications S.A., H1 2016 38
Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 39
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2016 40
Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2016 41
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 42
Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 43
Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2016 44
Neuroblastoma - Pipeline by Bionucleon Srl, H1 2016 45
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2016 46
Neuroblastoma - Pipeline by Cebiotex, S.L., H1 2016 47
Neuroblastoma - Pipeline by Celgene Corporation, H1 2016 48
Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 49
Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H1 2016 50
Neuroblastoma - Pipeline by CorMedix Inc., H1 2016 51
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 52
Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2016 53
Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2016 54
Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2016 55
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 56
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2016 57
Neuroblastoma - Pipeline by Green Cross Cell Corporation, H1 2016 58
Neuroblastoma - Pipeline by Ignyta, Inc., H1 2016 59
Neuroblastoma - Pipeline by Incuron, LLC, H1 2016 60
Neuroblastoma - Pipeline by Juno Therapeutics Inc., H1 2016 61
Neuroblastoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 62
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2016 63
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 64
Neuroblastoma - Pipeline by MediaPharma s.r.l., H1 2016 65
Neuroblastoma - Pipeline by MEI Pharma, Inc., H1 2016 66
Neuroblastoma - Pipeline by Merck & Co., Inc., H1 2016 67
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 68
Neuroblastoma - Pipeline by Morphogenesis, Inc., H1 2016 69
Neuroblastoma - Pipeline by Novartis AG, H1 2016 70
Neuroblastoma - Pipeline by Novogen Limited, H1 2016 71
Neuroblastoma - Pipeline by Pfizer Inc., H1 2016 72
Neuroblastoma - Pipeline by Pharmacyclics, Inc., H1 2016 73
Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 74
Neuroblastoma - Pipeline by Recombio S.L, H1 2016 75
Neuroblastoma - Pipeline by Ribomic Inc., H1 2016 76
Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2016 77
Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2016 78
Neuroblastoma - Pipeline by Syros Pharmaceuticals, Inc., H1 2016 79
Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 80
Neuroblastoma - Pipeline by Tiltan Pharma Ltd., H1 2016 81
Assessment by Monotherapy Products, H1 2016 82
Assessment by Combination Products, H1 2016 83
Number of Products by Stage and Target, H1 2016 85
Number of Products by Stage and Mechanism of Action, H1 2016 91
Number of Products by Stage and Route of Administration, H1 2016 95
Number of Products by Stage and Molecule Type, H1 2016 97
Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2016 274
Neuroblastoma - Dormant Projects, H1 2016 371
Neuroblastoma - Dormant Projects (Contd..1), H1 2016 372
Neuroblastoma - Dormant Projects (Contd..2), H1 2016 373
Neuroblastoma - Discontinued Products, H1 2016 374

Number of Products under Development for Neuroblastoma, H1 2016 19
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Products, H1 2016 29
Assessment by Monotherapy Products, H1 2016 82
Number of Products by Top 10 Targets, H1 2016 84
Number of Products by Stage and Top 10 Targets, H1 2016 84
Number of Products by Top 10 Mechanism of Actions, H1 2016 90
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 90
Number of Products by Routes of Administration, H1 2016 94
Number of Products by Stage and Routes of Administration, H1 2016 94
Number of Products by Top 10 Molecule Types, H1 2016 96
Number of Products by Stage and Top 10 Molecule Types, H1 2016 96

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +